FDA Accepts Supplemental NDA for CIBINQO (Abrocitinib) by Pfizer
The FDA has accepted a supplemental NDA for CIBINQO (abrocitinib), indicating progress in its regulatory review.
Asset / Drug
Drug and asset intelligence for CIBINQO with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
JAK Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.